Trifarotene, a retinoid of the fourth generation, in the treatment of acne: the first experience of use in a real clinical practice

The article presents data on the local retinoid of the fourth generation trifarotene. The results of three large trials have been presented, which have proven good efficacy and long-term safety of monotherapy of the drug trifarotene in patients with moderate acne and in patients with severe acne for combination therapy. It has been shown that trifarotene demonstrates high selectivity to retinoic acid receptors RAR-γ, which are predominant in the skin, which provides clinical efficacy in low concentration and good tolerability.